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Abstract
Nanomedicines have enormous potential to improve the precision of cancer therapy, yet our
ability to efficiently home these materials to regions of disease in vivo remains very limited.
Inspired by the ability for communication to improve targeting in biological systems, such
inflammatory cell recruitment to sites of disease, we construct systems where synthetic biological
and nanotechnological components communicate to amplify disease targeting in vivo. These
systems are composed of ‘Signalling’ modules (nanoparticles or engineered proteins) that target
tumours and then locally active the coagulation cascade to broadcast tumour location to clot-
targeted ‘Receiving’ nanoparticles in circulation that carry a diagnostic or therapeutic cargo,
thereby amplifying their delivery. We show that communicating nanoparticle systems can be
composed from multiple types of Signalling and Receiving modules, can transmit information via
multiple molecular pathways in coagulation, can operate autonomously, and can target over 40-
fold higher doses of chemotherapeutics to tumours than non-communicating controls.
Advances in nanotechnology have produced a diverse toolkit of individual nanodevices with
unique electromagnetic properties 1–3 and the ability to encapsulate and programmably
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release a diversity of therapeutics,4–9 yet the ultimate biomedical efficacy of such devices
largely depends on their in vivo fate. Over the past three decades, approaches to targeting
nanomaterials in vivo have focused on tuning the properties of individual nanoparticles
including geometry, surface chemistry, ligand type and ligand density10–18. These materials
are typically administered as populations of >1 trillion nanoparticles to carry out identical,
competitive functions in vivo. Here, inspired by the power of communication to improve
targeting across multiple length scales in biological systems (e.g. insect swarming, immune
cell trafficking, platelet self-assembly), we considered the design of nanoparticle (NP)
systems that communicate to enhance in vivo diagnostics, regenerative medicines, and
therapeutics.
We set out to construct two-component nanosystems from well-characterized nanoparticle
and biological components, wherein Signalling modules would first target tumours and then
broadcast the tumour’s location to Receiving nanoparticles in circulation (Figure 1A). To
facilitate rapid and robust signal transmission in regions of tumour growth, we sought to
harness the machinery of an endogenous multi-step biological cascade to transmit
communications (Figure 1B) and selected the coagulation cascade due to its powerful signal
amplification, positive feedback, ubiquitous presence in plasma, and potential to operate
across multiple tumour types (Figure 1C). We hypothesized that two Signalling modules
could selectively activate the coagulation cascade in tumours: nanoparticles (gold nanorods)
that target tumours and convert external electromagnetic energy into heat in order to locally
disrupt tumour vessels; and engineered human proteins (tumour-targeted tissue factor) that
autonomously survey host vessels for angiongenic tumour receptors and, in their presence,
activate the extrinsic coagulation pathway (Figure 1C). Receiving modules were constructed
using two nanomaterial platforms: a prototypical imaging agent (magnetofluorescent iron
oxide nanoworms) and a prototypical therapeutic agent (doxorubicin-loaded liposomes). We
explored the potential to route communication to Receivers via two molecular pathways in
coagulation by developing peptide coatings that recognize fibrin directly and peptides that
target coagulation enzyme activity by acting as a substrate for the coagulation
transglutaminase Factor XIII (FXIII) (Scheme 1C).
We first set out to examine the capacity of Signalling modules to precisely induce
coagulation in tumours (Figure 2A). To test our hypothesis that photothermal heating of
gold nanorods (NRs) could disrupt tumour blood vessels to initiate extravascular
coagulation,19–22 we examined the transduction of tumour heating into localized coagulation
by evaluating fibrin deposition in tumours as a function of temperature (Figure 2A). Purified
fibrinogen (the precursor to fibrin) and albumin (an abundant blood protein unrelated to
coagulation) were labeled with unique near-infrared fluorochromes to allow simultaneous
assessment of coagulation-dependent and independent protein tropism to heated tumours.
Mixtures of fibrinogen and albumin were intravenously injected into athymic (nu/nu) mice
bearing bilateral human MDA-MB-435 tumours, after which one tumour was heated using a
temperature-controlled water bath. At 24 hours, mice were sacrificed and the relative levels
of tumour fibrin(ogen) and albumin were assessed fluorescently. We observed a marked
induction of fibrin(ogen) accumulation in tumours between 45oC and 53oC, with little
accompanying increase in albumin accumulation, indicating that heat specifically directed
coagulation cascade activation in tumours (Figure 2B, S1). Immunohistochemical staining
for fibrin(ogen) in tumours from uninjected mice corroborated these findings, demonstrating
that exogenous fibrinogen administration did not artificially drive accumulation in heated
tumours (Figure S1).
Having probed the thermal sensitivity of coagulation in tumours, we next investigated
whether tumour-targeted gold NRs could specifycoagulation to occur in tumour tissues.
Rod-shaped gold nanoparticles are precisely-tunable plasmonic nanomaterials that may be
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synthesized in bulk, have narrow size distributions, optical absorption coefficients 104–106-
fold higher than conventional organic fluorochromes19–21. Previously, we demonstrated that
polyethyleneglycol-coated gold NRs (PEG-NRs) have >17 hr circulation half-lives in mice
and can passively target tumours in mice via their fenestrated angiogenic blood vessels to
direct precise tumour heating with otherwise benign near-infrared (NIR) energy (Figure
S2). 2324,25 Because near-infrared light can penetrate several cm’s in human tissue, it
provides an attractive external input to actuate vascular disruption in tumours26. To examine
NR-directed coagulation, PEG-NRs (10 mg Au/kg) or saline were intravenously
administered to mice bearing bilateral MDA-MB-435 tumours (Figure 2C, 2D). After PEG-
NR clearance from circulation (72 hrs post-injection), fluorescent fibrinogen was
intravenously injected and the right flanks of mice were irradiated with near-infrared light
(~1 W/cm2), generating focal tumour surface temperatures of ~49 C in PEG-NR-injected
mice, while saline-injected tumour surface temperatures remained below ~37 C (Figure 2C).
At 24 hrs post-injection, irradiated tumours on NR-injected mice displayed localized
accumulation of fibrinogen (Figure 2D), while tumours with PEG-NRs or near-infrared
energy alone and peripheral tissues lacked this feature. Histopathological analysis revealed
that fibrin(ogen) deposition formed a broad interstitial mesh in heated tumours, indicating
that NR heating could disrupt tumour blood vessels to activate extravascular coagulation
(Figure S2).
We next investigated the potential for a biological Signalling module to autonomously
survey the host vasculature for angiogenic tumour receptors and, in their presence, engage
the extrinsic coagulation cascade. Such a system would operate without the need for any
external electromangetic inputs (e.g. near-infrared energy) and could potentially amplify
nanoparticle targeting to deep-seeded and disseminated cancers. We utilized a truncated,
tumour-targeted version of the human protein tissue factor (tTF-RGD), which harnesses an
RGD peptide motif to induce coagulation upon binding to angiogenic αvβ3 receptors27–31
(Figure 2E). When tTF is separated from essential cell surface lipid co-factors, its activity
towards Factor X activation diminishes by 5 orders of magnitude32. This nearly digital
dependence on cell surface localization has enabled tumour-targeted tTFs to specifically
activate coagulation in mouse cancer models and, recently, in human cancer patients27,28.
As with PEG-NR Signalling modules, we first probed the relative accumulation of
fluorescently-labeled fibrinogen and albumin in MDA-MB-435 tumours of mice injected
with varying doses of tTF-RGD proteins. At 24 hours after injection, we observed a
macroscopic appearance of hemorrhage in tumours on mice injected with tTF-RGD (>15 μg
tTF-RGD/mouse), corresponding to the tumour-specific accumulation of fibrinogen in
dendritic, vascular patterns, which were absent in control tumours (Figure 2F, 2G, S3).
Microscopically, this appearance of vascular coagulation was corroborated by the abundant
localization of fibrin(ogen) within tumour blood vessels (Figure 2G).
Together, we found that both PEG-NR and tTF-RGD Signalling modules produced tumour-
specific coagulation, highlighting the potential for localized coagulation to communicate the
tumour’s location to Receivers in circulation. We next set out to develop Receiving
nanoparticles that could efficiently target regions of coagulation to deliver therapeutics or
act as imaging agents (Figure 3A). Initially, magnetofluorescent iron oxide nanoworm
imaging agents (NWs) (Figure 3B top) were derivatized with a peptide substrate for the
coagulation transglutaminase Factor XIII (G-N-Q-E-Q-V-S-P-L-T-L-L-K-X-C-
Fluorescein)33–35 to enable Receiver incorporation into regions of active coagulation (Figure
3B bottom, S4). Having observed that external heating of tumours produced localized
coagulation, we utilized this response in an assay to assess the ability of Receivers to target
tumour coagulation prior to integrating them with Signalling modules. Mixtures of targeted
and untargeted NWs, labelled with unique near-infrared fluorochromes, were intravenously
injected into mice bearing two MDA-MB-435 tumours. Immediately following injection,
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one tumour was submerged in a temperature-controlled water bath for 20 min and mice were
dissected at 24 hrs for fluorescent organ imaging. We found that the accumulation of FXIII-
NW Receivers was sharply amplified at 45oC compared to FXIIIControl-NWs bearing
peptides without the essential glutamine for FXIII cross-linking (Figure 3C, 3D, S5),
enabling nearly an order of magnitude increase in tumour targeting compared to unheated
tumours. The specificity of heat-induced targeting to coagulation persisted up to 53oC,
although the magnitude of accumulation decreased (Figure 3E), likely indicating that higher
temperatures accelerated intravascular coagulation and occlusion, diminishing the perfusion
required for delivery of Receiving NWs into tumours. Histopathologically, FXIII- NWs
showed marked extravasation and interstitial spreading in heated tumours compared with
controls (Figure 3D, S5), illustrating the capacity of thermal energy to dismantle tumour
vascular barriers and direct abundant interstitial Receiver accumulation.
We also explored the feasibility of channelling communications via an alternative molecular
pathway in the coagulation cascade. NWs were derivatized with a fibrin-binding peptide
(Ac-d-d-d-G-Y-e-C-hyP-cY-G-L-C-Y-I-Q-K-Fluorescein) (Figure 3B) and tested in a similar
assay. Fibrin-binding Receiving NWs also exhibited nearly a 10-fold amplification of
targeting to heated tumours (Figure 3C, S5), with prominent extravascular accumulation
histopathologically (Figure S5).
We next constructed model therapeutic Receiving modules to provide amplified drug
delivery to regions of tumour coagulation. Therapeutic Receivers were developed by
synthesizing doxorubicin-loaded liposomes (LPs) with tethered active (FXIII) or inactive
(FXIIIControl) substrates (Figure S4, S6). Here, tumour heating to 45oC directed the
accumulation of over 40-times higher doses of doxorubicin in tumours compared with
unheated controls and significantly enhanced targeting over inactive FXIIIControl substrate-
modified LPs (Figure 3F).
Having developed Signalling and Receiving modules and characterized their function in
isolation, we proceeded to study the ability of integrated nanoparticle systems to
communicate and amplify tumour targeting in vivo (Figure 4A). We began by testing the
ability for communication to amplify the targeting of magnetofluorescent FXIII-NW
Receiving modules to tumours. PEG-NRs (or saline) were intravenously-injected into mice
bearing bilateral MDA-MB-435 tumours. After NR clearance from circulation (72 hrs),
mixtures of active and inactive Receiving nanoparticles (FXIII-NWs and FXIIIControl-
NWs) labelled with distinct near-infrared fluorochromes were co-injected intravenously,
followed by near-infrared irradiation of the entire right flank of the mouse (~0.75 W/cm2,
810 nm, 20 min) under infrared thermographic observation. At 96 hrs, the entire mouse and
then the individual explanted organs were fluorescently imaged (Figure 4B). Thermographic
surveillance of photothermal heating showed focal tumour heating only in NR-injected mice
(Figure 4C) and whole-animal imaging at 96 hrs revealed pronounced homing of FXIII-
NWs to NR-heated tumours, with over an order of magnitude increase in accumulation
above unirradiated contralateral tumours and tumours on saline-injected mice (Figure 4D,
4E, S7). Histologically, integrated nanoparticle systems produced intense regions of FXIII-
NW fluorescence relative to controls, particularly in tumour boundaries where blood vessels
were well perfused (Figure S8). Nanoparticle systems were found to be effective in
xenograft cervical tumour models as well, directing several fold amplification in homing of
targeted Receiving nanoparticles over untargeted controls (Figure S9).
We next probed the ability for autonomous communication between tTF-RGD Signalling
modules and FXIII-NW Receiving modules to amplify tumour targeting (Figure 4F). When
co-injected alongside FXIII-NW Receivers (Figure 4G), we find that tTF-RGD Signalling
modules amplify Receiver targeting by several fold over non-communicating controls and
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over NWs that are directly targeted by RGD-targeting ligands (Figure 4H, S10). Similar to
the fibrin(ogen) distribution observed during tTF-RGD Signalling module testing, FXIII-
NW Receivers injected alongside tTF-RGD proteins produced a dendritic pattern of
accumulation in tumours, corresponding to abundant intravascular localization
immunohistochemically (Figure 4H, 4I, 4J). This amplified vascular targeting was found to
be specific for tumours over normal organs and was absent when the coagulation-inhibitor
heparin was administered alongside Signalling and Receiving modules (Figure 4I, S10).
Further, we found that tTF-NGR Signalling modules, which target CD13 angiogenic
receptors, were also able to amplify Receiver targeting to tumours (Figure S10), highlighting
the capacity for autonomously-communicating systems to be customized for specific
molecular cancer signatures.
As a proof of principle that nanoparticle communication could improve tumour drug
delivery and therapy, we studied the efficacy of a therapeutic communicating nanosystem
(Figure 5A). We found that communication between NR Signalling modules and FXIII-LP
Receivers amplified the accumulation of doxorubicin in tumours by over 40-fold (~8% ID/
g) as compared to the LPs alone (Figure 5B) and >6-fold when compared to an optimized
liposome formulation that targeted endogenous vascular receptors (αvβ3 for high affinity
cyclic-RGD peptide-targeted LPs), illustrating the potential for nanoparticle communication
to amplify drug delivery over nanoparticles directly targeted to tumour receptors (Figure
S11). This amplification of drug delivery likely has at least two components: heat-dependent
increases in passive accumulation due to improved extravasation in tumours (as indicated by
FXIIIControl-LPs and consistent with previous observations22) and specific biochemical
recognition of the coagulation process by the peptide coating. Histologically, FXIII-LPs
formed a broad interstitial mesh in NR-heated tumours, with released doxorubicin
fluorescence emanating from the nuclei of surrounded tumour cells, confirming the delivery
and release of active drug within tumour tissues (Figure 5C).
We finally evaluated the therapeutic efficacy of communicating nanoparticles in mice
bearing single MDA-MB-435 human carcinoma tumours. PEG-NRs (10 mg/kg) or saline
were injected into mice and, once NRs had cleared from circulation (72 hrs), a single
intravenous dose of FXIII- LPs, FXIIIControl -LPs, or saline (2 mg/kg doxorubicin) was
given, followed immediately by irradiation with near-infrared energy (~0.75 W/cm2, 810
nm, 20 min). We found that a single treatment with communicating nanoparticles directed a
prolonged inhibition of tumour growth that was significantly more effective than system
components in isolation (FXIII-LPs, FXIIIControl-LPs, NRs) and non-communicating
control systems (NRs + FXIIIControl-LPs) (Figure 5D, 5E) (p<0.02 for NR + FXIII-LPs
compared to all other treatment groups at each day from 5–24 after treatment; one-sided t-
test) without detectable weight loss due to systemic toxicity (Figure S11).
Inspired by communication in biological systems, we devised the first nanoparticle systems
that communicate to amplify tumour targeting. We demonstrate that systems of synthetic
human proteins and simple nanoparticles can be engineered to transmit information through
endogenous biological pathways by acting as artificial inputs and outputs to the coagulation
cascade. In contrast with ‘combination’ therapies where multiple disease pathways in the
host are targeted simultaneously, our strategy is composed of components that communicate
with one another to more efficiently target regions of disease. We found that communication
via the coagulation cascade enhanced the accumulation of Receiving modules in tumours by
up to 40-fold relative to Receiving modules tested in the absence of communication (Figure
S12), Further, we found that, after subtracting the baseline targeting of Receivers without
communication, each NR Signalling module in a host tumour was able to recruit >150
FXIII- NWs or >35,000 doxorubicin molecules encapsulated within FXIII- LPs (Figure
S12), demonstrating the capacity for signal amplification in our approach. Similarly, each
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tTF-RGD Signalling module that accumulated in a host tumour was able to recruit >10
FXIII- NWs via induction of localized coagulation (Figure S12). The ability for each tumour
receptor-targeted tTF-RGD Signalling module in our system to recruit many nanoparticle
Receiving modules contrasts to conventional strategies for ligand-mediated nanoparticle
targeting where, depending on nanoparticle valency, one or fewer nanoparticles are
delivered per ligand-bound receptor in tumours.
We believe this work motivates a new paradigm of ‘systems nanotechnology’ directed
toward the construction of communicative diagnostic and therapeutic agents with
sophisticated in vivo behaviours. Given the diverse nanoparticle and synthetic biological
‘building blocks’ under development13–18,36–38, coupled with the plethora of robust
biological cascades that could be re-purposed to enable communication between synthetic
components, we believe that a wide array of nanosystems could be engineered to more
sensitively locate, diagnose, and treat a diversity of focal human diseases.
Materials and Methods (detailed methods provided in Supplemental
Materials)
Signalling Module Synthesis
Long-circulating PEG-NRs were synthesized with 5kDa mPEG-thiol coatings as described
previously(23) and tTF-RGD and tTF-NGR Signalling modules were expressed in
engineered Escherichia coli, purified, and tested in vitro to verify purity (>95%) and activity
(Factor-X coagulation test) as described in Supplemental Materials.
Receiving Module Synthesis
Peptide Synthesis—The three peptides used in this work were synthesized via FMOC
solid-phase peptide synthesis, HPLC-purified to >90% purity, and characterized via mass
spectrometry as described in Supplemental Materials.
Iron oxide NW synthesis—Superparamagnetic, dextran-caged iron oxide nanoworms
(NWs) with a longitudinal size of ~55 nm were synthesized, aminated using 20% v/v
ammonium hydroxide, and derivatized with near-infrared fluorophores as described
previously(11). All peptide-functionalized NWs were characterized via dynamic light
scattering (DLS) and intravenously injected in vivo to ensure all targeted NWs and control
NWs exhibited similar circulation times. NIR-fluorophore and peptide attachment protocols,
along with NW purification methods, provided in Supplemental Materials.
Doxorubicin-loaded liposome synthesis—Hydrogenated soy sn-glycero-3-
phosphocholine (HSPC), cholesterol, and 1,2-distearoyl-snglycero-3-phosphoethanolamine-
N-polyethylene glycol 2000 [DSPE-PEG(2k)], 1,2-Distearoyl-sn-Glycero-3-
Phosphoethanolamine-N-[Maleimide(Polyethylene Glycol 2000)] [DSPE-PEG(2k)-MAL]
were purchased from Avanti Polar Lipids (Alabaster, AL). Doxorubicin was purchased from
Sigma Chemical Co. (St.Louis, MO). Briefly, for targeted LP synthesis, liposomes with
maleimide groups were prepared from HSPC, cholesterol, DSPE-PEG(2k), and DSPE-
PEG(2k)-MAL by lipid film hydration and membrane extrusion. Encapsulation of
doxorubicin (DOX) into the liposomes was then carried out using a pH gradient-driven
loading protocol. Free doxorubicin was removed by gel filtration on Sephadex G-50 and the
maleimide-terminated liposomes were reacted with thiols on peptides (FXIII and
FXIIIControl) for 2 hrs and then purified by gel filtration.
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In Vivo Studies
All studies in mice were approved by the Massachusetts Institute of Technology Committee
on Animal Care. MDA-MB-435 human cancer cells were cultured as recommended by
ATCC and injected into nu/nu mice to establish xenograft tumours as described previously
(3, 11, 23).
Signalling module distribution and bioactivity in vivo—Signalling module
biodistribution and fibrinogen coagulation assays are provided in Supplemental Materials.
Immunohistochemical analysis in tumours—For histologic analysis, frozen sections
of tumours were prepared. The sections were first fixed with acetone. Rat anti-mouse CD-31
(1:50, BD PharMingen) and biotinylated mouse fibrin(ogen) antiserum (1:50, Nordic) were
used for immunochemical staining of tumour tissue sections. The corresponding secondary
antibodies were added and incubated for 1 hour at room temperature: AlexaFluor-594 goat
anti-rat or rabbit IgG (1:1,000; Molecular Probes), streptavidin Alexa Fluor 594 (1:1000;
Molecular Probes). The slides were washed three times with PBS and mounted in
Vectashield Mounting Medium with DAPI. At least three images from representative
microscopic fields were analyzed for each tumour sample.
Imaging Receiving NW homing to tumours—Mixtures of NIR-fluorophore-labelled,
targeted and control NWs (bearing VT750 and VT680 or VT680 and VT750, respectively)
were co-adminstered intravenously in PBS (2 mg Fe/kg) to tumour-bearing nu/nu mice to
provide an internal control reference for coagulation-specific NW homing. At 24 hrs post-
NW injection, mice were sacrificed and organs were analyzed for both NIR-fluorophores
(LI-COR Odyssey Infrared Imaging System). For integrated nanoparticle system
characterization, mice were additionally imaged under isofluorane anaesthetic before
euthanization using a whole animal fluorescence reflectance imaging system (Xenogen,
IVIS Imaging System) to visualize the specificity of NW homing to tumours. Images from
both organ scanning and whole animal imaging are displayed throughout the manuscript as
overlaid green/red images from both fluorescence channels (VT750=green and VT680=red).
For autonomously-communicating nanosystems, NIR-fluorophore-labeled peptide-bearing
NWs (bearing VT750 fluorophores) were intravenously (2 mg Fe/kg) in PBS to
unanaesthetized MDA-MB-435 tumour-bearing nu/nu mice alone or alongside various tTF
Signalling modules (25 μg). At 24 hrs post-NW injection, mice were sacrificed and organs
were analyzed for NIR Receiver fluorescence (LI-COR Odyssey Infrared Imaging System).
For intraoperative fluorescent tumour imaging, mice were anaesthesized and tumours were
surgically exposed to reveal detailed tumour fluorescence (LI-COR). For whole animal
organ distribution, tTF-RGD Signalling modules were administered intraperitoneally (25
μg) and FXIII-NWs were administered intravenously (2 mg Fe/kg) to mice bearing a single
MDA-MB-435 tumour.
Quantification of Receiver homing to tumours—Protocols for fluorescent
quantification of NW and doxorubicin quantification provided in Supplemental Materials.
Therapeutic assessment of communicating and control nanoparticle systems
—Therapeutic studies were conducted by first intravenously administering PEG-NRs or
saline into nu/nu mice bearing a single MDA-MB-435 tumour. At 72 hrs post-injection,
mice were intravenously administered FXIII- LPs, FXIIIControl- LPs, or saline (in ~150 μl
bolus) and broadly irradiated in the vicinity of the tumour with NIR light (810 nm, ~1 W/
cm2, 20 min). An additional cohort of mice was administered saline at 0 and 72 hrs and not
exposed to NIR light in order to isolate any therapeutic efficacy of this input in isolation. At
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regular intervals after treatment, tumours were measured and mice were weighed. Mice were
sacrificed when tumours exceeded 500 mm3.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Nanoparticle communication for amplified tumour targeting
A) Schematic representation of communication between system components. Tumour-
targeted Signalling nanoparticles broadcast tumour location to Receiving nanoparticles in
circulation. B) Harnessing a biological cascade to transmit and amplify nanoparticle
communications. C) Molecular signalling pathway between Signalling and Receiving
components. Signalling and Receiving components act as unnatural inputs and outputs to the
coagulation cascade, respectively. Signalling components are either tumour-targeted
plasmonic gold nanorods (NRs), which initiate coagulation cascade activation in tumours by
photothermally disrupting tumour vessels and activating the extrinsic and intrinsic
coagulation pathways, or tumour-targeted truncated tissue factor proteins, which are latent in
circulation and activate the extrinsic coagulation pathway upon binding to tumour receptors.
Communication is exploited to recruit inorganic (iron oxide nanoworms) or organic (drug-
loaded liposomes) Receiving components via activity of the coagulation transglutaminase
FXIII or via targeting of polymerized fibrin.
von Maltzahn et al. Page 10
Nat Mater. Author manuscript; available in PMC 2012 May 29.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. ‘Signalling’ component characterization
A) Schematic of nanorod-directed coagulation and transmission electron microscopy of
near-infrared absorbing nanorods. Gold nanorods (NRs) are targeted to tumours to specify
local coagulation cascade activation via photothermal conversion of near-infrared energy. B)
Probing the coagulation-dependent and -independent protein tropism to heated tumours.
Fibrinogen and albumin were labelled with unique near-infrared fluorochromes and injected
into mice bearing bi-lateral MDA-MB-435 tumours. Immediately following injection, one
tumour on each mouse was heated using a temperature-controlled water bath. At 24 hrs post-
injection, mice were dissected and tumours imaged for the relative abundance of fibrinogen
(green) and albumin (red). C). Thermographic imaging of PEG-NR- and saline-injected
mice under near-infrared irradiation of the right flank. D) Fluorescence reflectance imaging
of mice to visualize fibrinogen tropism to PEG-NR-heated tumours. E) Schematic of
tumour-targeted tissue factor stimulation of the coagulation cascade in response to tumour
receptors. Signalling components are ligand-targeted, truncated human tissue factor proteins
(tTF-RGD) proteins that are latent in circulation and autonomously gain coagulation-
inducing activity upon binding to αvβ3 receptors in tumour blood vessels and associating
with endothelial cell surface phosphatidylserine. F) Intraoperative images at 24-hrs post-
tissue factor injection revealing tTF-RGD-mediated haemorrhaging. G) Probing the
coagulation-dependent and -independent protein tropism to tumours on tTF-RGD-injected
mice. tTF-RGD Signalling components were injected intravenously at varying doses
alongside mixtures of fluorescent fibrinogen (green, VT750) and albumin (red, VT680) to
monitor tTF-RGD-mediated coagulation in tumours. H) Histopathologic analysis of tumour
fibrinogen distribution without (left) and with 25μg tTF-RGD Signalling component co-
injection (right) (Red = CD31 blood vessel stain; Green = injected fibrinogen fluorescence;
Blue = nuclear stain; scale bars=100 μm)
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Figure 3. ‘Receiving’ component synthesis and testing
A) Schematic of Receiving NP homing to regions of coagulation. Nanoworm (NW) imaging
agents and drug-loaded liposomes (LPs) (top and bottom, respectively) were derivatized
with coagulation-targeting peptides to form Receiving NPs. B) Nanostructure and targeting
ligands of Receiving NPs. Transmission electron microscopy images of the two classes of
nanomaterials utilized in Receiving NP synthesis: iron oxide nanoworms (NWs; scale
bar=50 nm) and doxorubicin-loaded liposomes (LPs; scale bar=400 nm). Two peptides were
utilized to generate Receiving NPs: a fibrin-binding peptide and a glutamine-containing
substrate for the coagulation transglutaminase FXIII to respectively direct particle binding
and covalent attachment in regions of coagulation. C) Fluorescence reflectance imaging of
Receiving NP homing to externally-heated tumours. Mixtures of targeted (green) and
untargeted (red) NWs, labelled with the unique NIR-fluorochromes VT750 and VT680,
respectively, were intravenously injected into mice bearing bilateral MDA-MB-435
tumours. Immediately following injection, one tumour was submerged in a temperature-
controlled water bath for 20 min and mice were dissected at 24 hrs for fluorescent organ
imaging. Overlaid fluorescence images are shown for targeted (green) and untargeted (red)
Receiving NP accumulation in both heated (+, 45oC heating) and naïve (−) tumours from
the same mouse. D) Histopathological analysis of Receiving NP homing to heated tumours.
Histological sections from naïve (top) and heated (bottom, 45oC) tumours in FXIII-NW-
injected mice were stained for CD31 (red) and nuclei (blue) and imaged to reveal Receiving
NP distribution (green). (Scale bars = 100 μm) E) Quantifying the amplification of FXIII-
NW and FXIIIControl-NW Receiver homing to heated over unheated tumours. The fold
enhancement of NW targeting is plotted across the range of temperatures tested (p=0.02 and
0.03 for the difference between FXIII- -NWs and FXIIIControl-NWs at 45oC and 49oC,
respectively; paired, two-sided t-test, n=4; error bars=std. dev.). F) Quantifying the
amplification of FXIII-LP and FXIIIControl–LP (Drug-loaded Liposome) Receiver homing
to heated over unheated tumours. The fold enhancement of doxorubicin accumulation in
von Maltzahn et al. Page 12
Nat Mater. Author manuscript; available in PMC 2012 May 29.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
tumours is plotted across the range of temperatures tested for FXIII- LPs and FXIIIControl -
LPs (p=0.025 and p=0.049 for the difference between FXIII- NWs and FXIIIControl-NWs
at 45oC and 49oC, respectively; unpaired, two-sided t-test, n=3; error bars=std. dev.).
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Figure 4. Amplified tumour targeting with two systems of communicating nanoparticles
A) Schematic of communicating nanoparticles. B) Experimental timeline for testing
communicating nanoparticles. C) Thermographic imaging of photothermal PEG-nanorod
heating. At 72 hrs post NR- or saline-injection (10 mg Au/kg), mice were co-injected with
coagulation-targeted (FXIII- NWs) and untargeted (FXIIIControl-NWs) and their right
flanks were broadly irradiated (810 nm, ~0.75 W/cm2, 20 min) under infrared thermographic
surveillance to reveal surface temperatures. D) Overlaid fluorescence reflectance image of
targeted and untargeted Receiving NP homing. At 24 hrs post-irradiation, whole-animal
fluorescence imaging revealed the distributions of coagulation targeted (FXIII-NWs, green)
and untargeted (FXIIIControl-NWs, red) Receiving NPs. E) Quantification of Receiving NP
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homing in irradiated vs contralateral unirradiated tumours. After whole-animal imaging,
mice were dissected and the fluorescence of each tumour was measured to quantify the
homing of Receiving NPs. (* indicates p=0.02, paired, two-sided t-test; n=4; error bars=std.
dev.) F) Schematic of a nanosystem that communicates autonomously in the presence of
tumour receptors. G) Experimental timeline for testing the autonomous nanosystem in vivo.
H) Intraoperative imaging of NW Receivers. Nu/nu mice bearing a single MDA-MB-435
tumour were intravenously injected with communicating (tTF-RGD + FXIII-NWs) or
control (tTF-RGD + FXIIIControl-NWs) systems, FXIII-NWs alone, or NWs targeted by
the peptide used to direct Signalling component tumour homing (1 mg/kg tTF-RGD). At 24
hrs post-injection, tumours were surgically exposed for fluorescent intraoperative imaging of
NW homing. (FXIIICont-NWs = FXIIIControl-NWs) I) Tumour specificity of the
autonomous nanosystem. Excised organs from mice injected with autonomously
communicating nanosystems (tTF-RGD + FXIII-NWs) were imaged for NW fluorescence at
24 hrs post-injection (1 mg/kg tTF-RGD). J) Histopathological analysis of NW Receivers.
Histopathological sections from experiments in H). At 24 hrs post-NW injection, mice were
sacrificed and tumours were analyzed for NW Receiver distribution in histology. (Red=
CD31 blood vessel stain, Blue= DAPI nuclear stain, Green=NW Receiver distribution,
RGD-NW scale bar=100 μm; All others = 200 μm)
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Figure 5. Amplified tumour therapy with communicating nanoparticles
A) Schematic of therapeutic system of communicating nanoparticles B) Quantification of
doxorubicin-loaded LP Receiver homing in irradiated vs contralateral unirradiated tumours.
At 96 hrs after Signalling NP injection, mice were dissected and the doxorubicin
fluorescence of each tumour homogenate in acidic ethanol was measured to quantify the
homing of Receiving NPs. (* indicates p=0.021, unpaired, two-sided t-test, n=4; error
bars=std. dev.) C) Histopathological analysis of NR-directed FXIII- LP targeting and
doxorubicin delivery. Histopathological sections from the integrated NP signalling
experiments in B). At 24 hrs post-NW injection, mice were sacrificed and tumours were
analyzed for FXIII-LP and doxorubicin distributions in histology. (Red= doxorubicin, Blue=
DAPI nuclear stain, Green=FXIII- LP distribution). (Scale bars = 100 μm). D) Tumour
volumes following a single treatment with communicating nanoparticle systems and
controls. Tumours in all treatment groups except Saline (laser) were exposed to near-
infrared irradiation for 20 min (~0.75 W/cm2, ~810 nm, arrow) 72 hrs after i.v. nanorod or
saline injection (p<0.05 for NR + FXIII-LPs and all other treatment sets between days 8 and
24; ANOVA, n=7 mice in each set). E) Representative images of mice treated with
communicating nanoparticles (NRs + FXIII-LPs, below) compared with untreated controls
(Saline, above) (20 days post-treatment).
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